Xavier Badia - Oblikue Consulting | 人才画像

基本信息

浏览量：177

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 367 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

The Value of the Reflective Discussion in Decision-Making Using Multi-Criteria Decision Analysis (MCDA): an Example of Determining the Value Contribution of Tabelecleucel for the Treatment of the Epstein Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Xavier Badia,Miguel Ángel Calleja,Vicente Escudero-Vilaplana,Antonio Pérez-Martínez, José Luis Piñana,José Luis Poveda, Joan-Antoni Vallès

Orphanet Journal of Rare Diseasesno. 1 (2024): 1-13

引用0浏览0WOS引用

Value Contribution of Etranacogene Dezaparvovec Gene Therapy in Moderately Severe and Severe Haemophilia B Through Multi-Criteria Decision Analysis

Daniel-Anibal Garcia-Diego,Xavier Badia,Olga Benitez-Hidalgo, Victor Jimenez, Juan Carlos Juarez,Ramiro Nunez,Jose Luis Poveda,Jose Luis Trillo, Joan-Antoni Valles

HAEMOPHILIA (2024)

引用0浏览0WOS引用

EE434 the Cost-Effectiveness of Atidarsagene Autotemcel (Arsa-Cel) for the Treatment of Metachromatic Leukodystrophy (MLD) in Spain

K Bean,A Olaye, B Miller,I Jensen, G Muduma, A Giró,F Pang,X Badia

Value in Healthno. 12 (2024): S141

引用0浏览0引用

HTA297 Value Contribution of Etranacogene Dezaparvovec for the Treatment of Severe and Moderately Severe Haemophilia B in Spain Through Multicriteria Decision Analysis (MCDA)

Daniel-Anibal Garcia Diego,Victor Jimenez-Yuste,Ramiro Nunez Vazquez,Olga Benitez Hidalgo,Jose Luis Poveda,Juan Carlos Juarez Gimenez,Jose Luis Trillo, Joan-Antoni Valles, Rafael Perez-Santamarina,Xavier Badia

HAEMOPHILIA (2024): 62-62

引用0浏览0引用

Incidence and Management of Patients with Methotrexate Delayed Elimination in the Clinical Practice: A Delphi Study

Luis Gros,Alicia Roldan,Almudena Cabero-Martinez,Nerea Dominguez-Pinilla,Adolfo de la Fuente,Eva Gonzalez-Barca,Maria Tasso,Montserrat Torrent,Eva Gallardo, Ines del Cerro,Ariadna Giro-Perafita,Xavier Badia

JOURNAL OF ONCOLOGY PHARMACY PRACTICE（2023）

引用9浏览0WOS引用

EE394 Understanding Reasons of Negative Reimbursement Decisions for Orphan Drugs in the Spanish National Health System (APRIL 2019-MAY 2023)

A. Gil, Á Pérez,X. Badia

Value in Healthno. 12 (2023): S126-S126

引用0浏览0引用

ODs with a Positive TPR Conclusion, Not Subject to a Conditional Approval, and Approved Without Requering a Pass Would Be More Likely to Be Reimbursed in Spain

Poveda José Luis, Gómez Claudia,Gil Alicia,Badia Xavier

ORPHANET JOURNAL OF RARE DISEASES（2023）

引用1浏览0WOS引用

Revisión De Los Programas De Acceso Temprano a Los Medicamentos Innovadores En Europa: ¿es Hora De Revisar El Proceso En España

X. Badia,A. Gil, M. Blasco

Economía de la Salud (2023)

引用0浏览0引用

Contribución De Valor De Olipudase Alfa En El Tratamiento De Las Manifestaciones No Relacionadas Con El SNC Del Déficit De Esfingomielinasa Ácida Mediante Análisis De Decisión Multicriterio

Jesús Villarubia, María Reyes-Abad,Antonio González-Meneses, Elena Gras-Colomer,José L. Poveda,José L. Trillo, Daniel de Vicente, Mateo Baret,Ariadna Giró-Perafita,Xavier Badia

Revista Sangre（2023）

引用0浏览0引用

Use of Hospital Resources in ICU Inpatients with Infections Caused by Carbapenem-Resistant Gram-negative Bacteria: A Real Clinical Practice-Based Study in Spain

Ricard Ferrer,Jose Garnacho-Montero,Pedro Rascado,Sofia Contreras,Luisa Canton-Bulnes, Patricia Barral, Ines del Cerro,Xavier Badia

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA（2023）

引用2浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn